US Stock MarketDetailed Quotes

VTGN VistaGen Therapeutics

Watchlist
  • 2.6900
  • +0.0900+3.46%
Close Nov 27 16:00 ET
  • 2.6900
  • 0.00000.00%
Post 20:01 ET
74.90MMarket Cap-3635P/E (TTM)

VistaGen Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

VistaGen Therapeutics Q2 2025 Earnings Date

Currency：USDNov 7, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
33.33K
183.00K
+149.67K
Beat Est.
-88.00%
-34.17%
+449.05%
EPS
-0.39
-0.42
-0.03
Miss Est.
+40.92%
+36.36%
-7.72%
Analyst Rating
Buy

Nov 21, 2024

VistaGen Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 4 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q4-- / 179.250K--
--2025/Q3-- / 179.250K--
Nov 7, 20242025/Q2183.000K / 33.330K--
Aug 13, 20242025/Q184.000K / 298.500K--
Jun 11, 20242024/Q4197.300K / 202.750K--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q4-- / 179.250K--
--2025/Q3-- / 179.250K--
Nov 7, 20242025/Q2183.000K / 33.330K--
Aug 13, 20242025/Q184.000K / 298.500K--
Jun 11, 20242024/Q4197.300K / 202.750K--

Unlock Free Earnings Estimates

VistaGen Therapeutics Earnings Reports

  • VistaGen Therapeutics | 8-K: Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

    Nov 7 22:38 ET

  • VistaGen Therapeutics | 10-Q: Q2 2025 Earnings Report

    Nov 7 16:38 ET

  • VistaGen Therapeutics | 8-K: Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update

    Aug 13 16:57 ET

  • VistaGen Therapeutics | 10-Q: Q1 2025 Earnings Report

    Aug 13 16:52 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Nov 21, 2024

    Buy

    • Buy

      100.00%

    • Hold

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg

    No Data